![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
September 17, 2024
Fall Comis Symposium to focus on inflammation as a cause of cancer; ECOG-ACRIN readies for NCTN Grant resubmission
September 17, 2024
A conversation with study chair James M. Ford, MD
September 17, 2024
This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
September 17, 2024
A recent amendment expands eligibility for this phase 2 trial evaluating the use of green tea catechin pills to help prevent progression
September 17, 2024
Summaries of recently published ECOG-ACRIN research results
September 17, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more